CHMP adopts positive opinion on expanding indication for Pfizer's Prevenar 13

23 January 2015
pfizer-logo-big

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion on expanding the indication for Pfizer’s (NYSE: PFE) Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]).

The CHMP recommends that the indication be expanded to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older.

The drug is currently approved in Europe to prevent invasive pneumococcal disease in the same population. The CHMP’s positive opinion is now to be reviewed by the European Commission, who will make the decision of whether to approve Prevenar 13 for this indication.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical